In short
Clinical trials investigating HYDROXYCHLOROQUINE are included here as part of studies in rheumatoid arthritis. These trials look at treatment effects, safety, and patient response in specific study groups. The article focuses on who was studied, what phase the trial was in, and which outcomes were measured.
Key points
- Clinical trial data for HYDROXYCHLOROQUINE appears in a Phase 3 study in rheumatoid arthritis. That study was randomized, placebo-controlled, and double-blind, and it enrolled 189 patients with moderately to severely active disease. The main endpoint was ACR20 at Week 12, which measures improvement in arthritis symptoms. Another Phase 3 trial in idiopathic inflammatory myopathy included HYDROXYCHLOROQUINE among many allowed treatments, but its main focus was long-term safety of dazukibart. Across the data, the trials focus on treatment response, safety, and patient outcomes in specific disease groups.
Trial overview
The available trial data shows HYDROXYCHLOROQUINE used in a Phase 3 study for rheumatoid arthritis and listed as one of several drugs in another Phase 3 study for idiopathic inflammatory myopathy, including dermatomyositis and polymyositis.
These trials are not about the drug alone as a stand-alone topic. They are part of larger research studies that compare treatments, check response, and measure safety in specific patient groups.
Rheumatoid arthritis study
One completed trial was a randomized, placebo-controlled, double-blind, parallel group study in patients with moderately to severely active rheumatoid arthritis.
This means people were assigned by chance to different study groups, a placebo was used for comparison, and neither the participants nor the study team knew who received which treatment during the study.
The study enrolled 189 participants and tested the efficacy and safety of subcutaneous CT-P13, while HYDROXYCHLOROQUINE was one of the listed study drugs used in the trial setting.
The trial was completed.
Idiopathic inflammatory myopathy extension study
Another trial was an open-label extension study in people with idiopathic inflammatory myopathies, including dermatomyositis and polymyositis, who had already finished the treatment period of a qualifying parent study.
This study was authorised, was in Phase 3, and enrolled 182 participants.
Its brief goal was to evaluate the long-term safety of dazukibart in people with dermatomyositis or polymyositis, while the intervention list also included HYDROXYCHLOROQUINE among many other medicines used in the study context.
Outcomes and endpoints
The main result in the rheumatoid arthritis trial was the proportion of patients who reached ACR20 at Week 12.
ACR20 means at least a 20% improvement in arthritis signs and symptoms, so it is a simple way to measure whether treatment helped patients.
In the myopathy extension study, the primary outcomes focused on safety and monitoring, including TEAEs, SAEs, AESIs, lab test changes, ECG measurements, vital signs, lung function changes, and C-SSRS results.
TEAEs are treatment-emergent adverse events, SAEs are serious adverse events, and AESIs are adverse events of special interest.
The lung function measures included change from baseline in FVC and DLCO, and C-SSRS tracked suicidal thoughts and behavior at scheduled time points.
Study design terms
Open-label means that the people in the study and the study team know what treatment is being given.
Placebo-controlled means the trial used a non-active comparison treatment to help show whether the study treatment works better than no active treatment.
Parallel group means different groups were followed at the same time, rather than one group switching to another treatment later.
Extension study means a follow-up study after a parent trial, often used to collect longer-term data.
What patients should know
Based on the trial data, HYDROXYCHLOROQUINE appears as part of studies in two different disease areas: rheumatoid arthritis and idiopathic inflammatory myopathy.
The studies were in Phase 3, which is a later stage of clinical research that usually includes more participants and focuses on real treatment effects and safety monitoring.
The main questions were whether treatment helped patients, how safe it was, and how patients changed over time using standard outcome measures.